^
Association details:
| Biomarker: | CD20 positive |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Arzerra (ofatumumab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial
Excerpt:
With a median follow-up of 44 months (26-53), 4-year event-free survival was 59% (95% CI 48-73); 69% (54-87) in adolescents and young adults aged 18-39 years. 4-year overall survival was 68% (58-81); 74% (60-91) in adolescents and young adults. The overall response rate was 98% (64 of 65 patients)...The combination of hyper-CVAD plus ofatumumab is safe and active in adults with Ph-negative CD20-positive B-cell acute lymphoblastic leukaemia.
Secondary therapy:
CVAD
DOI:
10.1016/S2352-3026(20)30144-7
Trial ID:
